A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization.

Trial Profile

A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Aspirin-induced asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 01 Mar 2016 Protocol amended as treatment arm changed from 1 to 2, study design changed from single group to parallel as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top